Seagen International GmbH is the base for international operations of Seagen Inc., a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives.

Products, services, technology

Our lead product ADCETRIS® is marketed in >70 countries worldwide for certain types of CD30-expressing lymphomas. In 2020, we launched 2 new cancer medicines: PADCEV® for treatment of certain types of metastatic urothelial cancers and TUKYSA® for certain patients with HER2+ metastatic breast cancer.

Location

Dammstrasse 23, 6300 Zug, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2015

  • Number of employees in Switzerland

    50-149